Published in Vnitr Lek on May 01, 2008
8. Dyslipidemia at Chronic Renal Failure. EJIFCC (2009) 0.75
[Clinical spectrum of the antiphospholipid syndrome]. Cas Lek Cesk (1997) 1.39
Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol (2013) 1.05
Primary Sjögren's syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol (1999) 1.00
Trace elements in hemodialysis and continuous ambulatory peritoneal dialysis patients. Blood Purif (1998) 0.92
Trace elements in end-stage renal disease. 2. Clinical implication of trace elements. Blood Purif (1999) 0.92
Acute renal failure due to bilateral renal artery thrombosis associated with primary antiphospholipid syndrome. Nephrol Dial Transplant (1998) 0.92
Exposure to silica and risk of ANCA-associated vasculitis. Am J Ind Med (2006) 0.92
Culture methods of glomerular podocytes. Kidney Blood Press Res (2007) 0.91
Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis (2008) 0.90
Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma. Neoplasma (1996) 0.89
Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res (2009) 0.89
Cytokine profile in autosomal dominant polycystic kidney disease. Biochem Mol Biol Int (1997) 0.88
Mechanisms of chronic heart failure development in end-stage renal disease patients on chronic hemodialysis. Physiol Res (2008) 0.88
Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit (2001) 0.87
[Urinary tract infection in patients with diabetes mellitus]. Vnitr Lek (2006) 0.86
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus (2010) 0.86
Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities. Kidney Blood Press Res (2004) 0.86
[The production and properties of human immunoglobulin G-anti-D (Halle)]. Dtsch Gesundheitsw (1970) 0.85
Influence of endothelin-1 gene polymorphisms on the progression of autosomal dominant polycystic kidney disease. Kidney Blood Press Res (2006) 0.84
Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol Res (2003) 0.84
Clinical features and natural history of IgA nephropathy. Ann Med Interne (Paris) (1999) 0.84
Transjugular renal biopsy. Our experience with 67 cases. Kidney Blood Press Res (2001) 0.84
Chromium levels in patients with internal diseases. Biochem Mol Biol Int (1998) 0.83
ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats. Nephrol Dial Transplant (1998) 0.83
Incomplete distal renal tubular acidosis coinherited with a mutation in the band 3 (AE1) gene. Nephrol Dial Transplant (1997) 0.83
A novel method for the estimation of podocyte injury: podocalyxin-positive elements in urine. Folia Biol (Praha) (2008) 0.83
Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre. Int Urol Nephrol (2009) 0.82
Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients. Nephrol Dial Transplant (2003) 0.82
Influence of the alpha-adducin and ACE gene polymorphism on the progression of autosomal-dominant polycystic kidney disease. Kidney Blood Press Res (2003) 0.82
Genetic basis of nephrotic syndrome--review. Prague Med Rep (2006) 0.81
Event-related potentials in evaluation of metabolic encephalopathies. Schweiz Arch Neurol Psychiatr (1993) 0.80
Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol Res (2001) 0.80
Inflammatory cytokine profile in autosomal dominant polycystic kidney disease. Contrib Nephrol (1997) 0.80
[Lipid peroxidation and activity of antioxidative enzymes in patients with multiple myeloma]. Cas Lek Cesk (1996) 0.80
Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats. Physiol Res (2004) 0.80
Effect of acute hyperglycaemia on selected plasma and urinary cytokine antagonists in Type 1 diabetes mellitus. Diabetologia (2003) 0.80
Recent insights into the pathogenesis of nephrotic syndrome. Minerva Med (2013) 0.79
Trace elements in end-stage renal disease. 1. Methodological aspects and the influence of water treatment and dialysis equipment. Blood Purif (1999) 0.79
Preeclampsia, dilated cardiomyopathy and renal failure as the first manifestation of systemic lupus erythematosus: a case report. Clin Rheumatol (2008) 0.79
[Disorders of urinary acidification in patients with monoclonal gammapathies]. Cas Lek Cesk (2000) 0.79
The influence of cyclosporin on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Nephron (1997) 0.79
Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience. Prague Med Rep (2004) 0.78
Long-term treatment of IgA nephropathy with cyclosporin A--a preliminary report. Nephrol Dial Transplant (1997) 0.78
The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail (1998) 0.78
[Initial experience with the transjugular renal biopsy]. Cas Lek Cesk (1993) 0.78
ANCA-associated renal vasculitis--epidemiology, diagnostics and treatment. Prague Med Rep (2004) 0.78
Brain diffuse large B-cell lymphoma in a systemic lupus erythematosus patient treated with immunosuppressive agents including mycophenolate mofetil. Lupus (2011) 0.78
Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. Blood Purif (2004) 0.78
Effects of Doxorubicin (Adriamycin) and [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)]propane (ICRF-187) on skeletal muscle protease activities. Toxicol Appl Pharmacol (2001) 0.78
Long term treatment of IgA nephropathy with cyclosporine A. Ren Fail (2000) 0.77
Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus (1998) 0.77
Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease. Kidney Blood Press Res (2008) 0.77
Circulating endothelial cells and circulating endothelial progenitors in kidney disease--victims, witnesses, or accomplices? Folia Biol (Praha) (2008) 0.77
[The effect of a single administration of captopril on portal flow as measured by the Doppler method]. Cas Lek Cesk (1988) 0.77
Acute doxorubicin (adriamycin) dosage does not reduce cardiac protein synthesis in vivo, but decreases diaminopeptidase I and proline endopeptidase activities. Exp Mol Pathol (2001) 0.77
Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif (2002) 0.77
Antioxidant enzymes--superoxide dismutase and glutathione peroxidase--in haemodialyzed patients. Blood Purif (1996) 0.77
Advanced glycation end products in clinical nephrology. Kidney Blood Press Res (2004) 0.77
The influence of endothelin-A receptor gene polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Folia Biol (Praha) (2007) 0.77
Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats. Physiol Res (2005) 0.77
[Transjugular renal biopsy--initial experience]. Cas Lek Cesk (1994) 0.77
[Sleep disorders in patients treated with continuous ambulatory peritoneal dialysis]. Sb Lek (2001) 0.77
The influence of G-protein beta3-subunit gene and endothelial nitric oxide synthase gene in exon 7 polymorphisms on progression of autosomal dominant polycystic kidney disease. Ren Fail (2004) 0.77
The influence of two megsin polymorphisms on the progression of IgA nephropathy. Folia Biol (Praha) (2008) 0.77
[Soluble adhesion molecules in female patients with breast carcinoma]. Cas Lek Cesk (2003) 0.76
Local hemodynamics of the vascular access for hemodialysis. Kidney Blood Press Res (2009) 0.76
[Sleep disorders in hemodialysis patients]. Cas Lek Cesk (2001) 0.76
Can serum amyloid A or macrophage colony stimulating factor serve as marker of amyloid formation process? Biochem Mol Biol Int (1999) 0.76
The influence of the endothelin-converting enzyme-1 gene polymorphism on the progression of autosomal dominant polycystic kidney disease. Ren Fail (2006) 0.76
The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy. Folia Biol (Praha) (2007) 0.76
Endotelial activation and flow-mediated vasodilation in young patients with breast cancer. Neoplasma (2013) 0.75
[Acute phase proteins in female patients with breast carcinoma]. Sb Lek (2003) 0.75
Ethylene glycol poisoning in the Czech Republic (2000-2002). Blood Purif (2005) 0.75
Determination of copper, selenium and zinc in human blood by inductively coupled mass spectrometry: the sources of uncertainty and variability of results. Sb Lek (2000) 0.75
Two familial cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Rheumatology (Oxford) (2006) 0.75
[Reaction of the cardiovascular and humoral system to acute hypervolemia in patients with liver cirrhosis]. Cas Lek Cesk (1989) 0.75
[Serum antineutrophil cytoplasmic antibodies inhibit the ability of granulocytes to kill C. albicans]. Cas Lek Cesk (1994) 0.75
Atrial natriuretic factor and its role in the regulation of electrolyte, volume and pressure homeostasis. Czech Med (1989) 0.75
[The effect of a single administration of captopril on portal hemodynamic values]. Vnitr Lek (1988) 0.75
[Rhabdomyolysis and acute renal failure]. Cas Lek Cesk (1993) 0.75
[HLA-phenotypes of idiopathic thrombocytopenias in childhood]. Acta Biol Med Ger (1980) 0.75
[Lithium clearance as a parameter of hyper-resorption of sodium in the proximal tubules in liver cirrhosis]. Cas Lek Cesk (1988) 0.75
[Rapidly progressive glomerulonephritis in a solitary kidney positive for anti-glomerular basement membrane antibodies and antineutrophil cytoplasmic antibodies]. Cas Lek Cesk (1994) 0.75
[Effect of angiotensin-converting enzyme insertion-deletion polymorphism on progression of renal and cardiovascular diseases]. Cas Lek Cesk (2001) 0.75
[Plasma volume in polycystic kidney disease]. Sb Lek (1994) 0.75
[Atrial natriuretic factor in liver cirrhosis. The effect of volume loading]. Cas Lek Cesk (1988) 0.75
[Hypertension in patients with polycystic kidneys--the effect of volume expansion]. Sb Lek (1991) 0.75
[A simple method for determining the lithogenic index of bile]. Cas Lek Cesk (1983) 0.75
[The effect of peroral administration of isosorbide dinitrate on portal pressure and flow in patients with liver cirrhosis]. Cas Lek Cesk (1988) 0.75
[Acute kidney failure associated with rhabdomyolysis]. Cas Lek Cesk (1993) 0.75
[Repeated ergometric loading]. Vnitr Lek (1989) 0.75
[Mutual interaction of the renin-angiotensin system and the atrial natriuretic factor in the renal response to acute volume loading]. Vnitr Lek (1990) 0.75
Radioimmunoassay of atrial natriuretic peptide in human plasma: application to studies of volume and blood pressure homeostasis. Physiol Bohemoslov (1988) 0.75
[Mode of action of immunoprevention in anti-Rh-induced haemolytic disease of newborn infants]. Dtsch Gesundheitsw (1972) 0.75
[The significance of clinical findings in evaluating the degree of portal hypertension in patients with liver cirrhosis]. Cas Lek Cesk (1989) 0.75
[Lithium clearance in polycystic kidney disease]. Sb Lek (1994) 0.75
Antineutrophil cytoplasmic antibody-positive sera inhibit candidacidal activity of granulocytes. Exp Nephrol (1995) 0.75
[Distal renal tubular acidosis in patients with liver cirrhosis]. Cas Lek Cesk (1987) 0.75
[Hypertension in patients with polycystic kidneys--the effect of volume expansion]. Sb Lek (1991) 0.75